Member Info for mango

Seem to be a lot of large sell trades this morning.
Is something afoot?

Have also had AZ jab.
No side effects at all. Happy to have 2nd one.

Unfortunately it's not a question of whether we are worried but about sentiment in the EU.
Even before Covid there was a high level of anti vax sentiment in many European countries .
There has also been fear mongering by political parties in Italy and the fuss about AZ deliveries which undermined trust in the company and the vaccine. See the Guardian article below for some background.
https://www.theguardian.com/commentisfree/2021/feb/24/eu-covid-vaccination-difficulties-anti-vaxxers
However misguided it may be the EU governments are responding to their concerns of their citizens.
I am certain this will be resolved but it can only slow down vaccine rollout.. with the adverse consequences for SAGA of delaying a return to normality.
I remain a SAGA holder but it means we may have to wait a while longer for a rapid increase in the SP.

That's good to know, but how many potential patients have delayed seeking treatment in the first place by not going to their GP and starting the process of referral for surgery?
I think it's likely there is a significant amount of pent up demand for treatment in most areas of the NHS which will need to be met at some stage.

Clearly trending to 350 over the next 3 months.

hmm by some weird coincidence ,my shareholdnig divides exactly by 19 ..1 suppose that's a 1in 19 chance so not so miraculous !!

After the recent rise the P/E is about 60.
I'm out chaps, after the he inevitable plummet in the SP ,I may return.
Good luck if you are hanging on.

This vaccine study was only on fit young adults so basically has not been tested on people who are likely to get severe symptoms ...as this age group don't get them.
The researchers still believe that it will be effective in preventing severe infection ..but they have to wait for evidence of this after data from older subjects has been studied and analysed.

This is a very small clinical trial in one hospital.
As such this is very much a preliminary study, however encouraging it may be.
There will need to be several more larger studies confirming this result before this is adopted as a standard treatment.
Let's hope it really does do the business , because if so it's a real game-changer.

Under the terms of the Merger, holders will be issued with GBP 1.20 in cash in exchange for every McCarthy & Stone share held

The official pay day is 15th February 2021.
From ii corporate actions.
A sad end brought about by poor leadership.

.....eventually. hmm you can never be wrong with that type of prediction, can you.
The shorters are taking a hiding , oh dear what a shame,never mind..

BTW I just doubled my investment @ 2997 this morning.
Best wishes to all other long term holders.

So much bad news around now that any hint of blue skies will cause this stock to jump in price.

It’s not been a great week for GlaxoSmithKline’s partnered R&D projects; after being forced to cull a major lung cancer trial with Merck KGaA, it’s now a case of déjà vu as it axes yet another experimental drug study.

This time it’s with Immutep, an Australian biotech it has long roots with, as the two have an R&D pact stretching all the way back to late 2010. That deal centered on IMP731, which works by depleting LAG-3 positive cells.

https://www.fiercebiotech.com/biotech/glaxosmithkline-s-immutep-partnered-midstage-gi-med-culled-ulcerative-colitis
Continuing failure..not a good look for a company reliant on developing new products.

GlaxoSmithKline is losing another vaccine executive in the midst of developing a COVID-19 shot. This time, it’s Amir Reichman, head of global vaccines engineering core technologies, who will eventually take the helm at BiondVax Pharmaceuticals.

Reichman’s exit comes about five months after Jack Bailey, head of U.S. pharmaceuticals, left the British drugmaker. Bailey landed at cancer biotech G1 Therapeutics, taking over from its first CEO this month, while Reichman will share duties with BiondVax’s founder and CEO Ron Babecoff until March 2 as he winds down ...
https://www.fiercebiotech.com/biotech/another-gsk-vaccines-exec-jumps-ship-for-biotech-ceo-role.
..rearrange these words for a well known saying...
Sinking, leaving, ship,rats, a

Sounds like a conspiracy theory ...tinfoil hats anyone.

Tripling of China-Europe shipping costs threatens goods supply
Prices at record high fuelled by shortage of containers and recovery in consumer demand.
Hence the SP rise?

Less than a week to trading update lets hope it doesn't go horribly wrong :)...
Re member the old stockbrokers adage
"Buy on the rumour, sell on the news'.
We can expect a dip when the update is released, even if the news is good.
But this will temporary.

"there can surely be no justification for further lockdowns after March". Yes but March which year?
Further lockdowns will not need any "justification" as they will simply be decided on the numbers of people who are, sadly, dying .
We just won't know this till it happens and this will also depend on how the virus mutates.
The government is saying basically do not even think about relaxing restrictions for at least a month.
Boris's overoptimism (using my hindsight goggles) has unfortunately got us into the sorry state we are now and I think he won't want to repeat this mistake.
Consequently pubs and hotels may be the last thing to be freed from restrictions.

Dip in SP due to ...a broker rerating....??
Anyone know more.